Page Banner

United States Department of Agriculture

Agricultural Research Service

Title: Chimeric West Nile/dengue Virus Vaccine Candidate: Preclinical Evaluation in Mice, Geese, and Monkeys for Safety and Immunogenicity

Authors
item Pletnev, Alexander - NIH - BETHESDA, MD
item Swayne, David
item Speicher, Jim - NIH - BETHESDA, MD
item Rumyantsev, Alexander - NIH - BETHESDA, MD
item Murphy, Brian - NIH - BETHESDA, MD

Submitted to: Vaccine
Publication Type: Peer Reviewed Journal
Publication Acceptance Date: August 1, 2006
Publication Date: September 26, 2006
Citation: Pletnev, A.G., Swayne, D.E., Speicher, J., Rumyantsev, A.A., Murphy, B.R. 2006. Chimeric West Nile/dengue virus vaccine candidate: Preclinical evaluation in mice, geese, and monkeys for safety and immunogenicity. Vaccine. 24(40-41):6392-6404.

Interpretive Summary: A live attenuated virus vaccine is being developed to protect against West Nile virus (WN) disease in humans. Here, we report the development of the vaccine and evaluation for safety and immunogenicity in mice, geese, and monkeys. The vaccine candidate was safe in mice and monkeys but failed to infect geese. The vaccine was safe and readily induced neutralizing antibodies against WN in monkeys. These findings indicate the vaccine should be safe for both the recipient and the environment.

Technical Abstract: A live attenuated virus vaccine is being developed to protect against West Nile virus (WN) disease in humans. Previously, it was found that chimeric West Nile/dengue viruses (WN/DEN4 and WN/DEN4-delta-30) bearing the membrane precursor and envelope protein genes of WN on a backbone of dengue type 4 virus (DEN4) with or without a deletion of 30 nucleotides (delta-30) in the 3-prime non-coding region of the DEN4 part of the chimeric genome were attenuated and efficacious in mice and monkeys against WN challenge. Here, we report the generation of a clinical lot of WN/DEN4-delta-30 virus and its further preclinical evaluation for safety and immunogenicity in mice, geese and monkeys. The vaccine candidate had lost neuroinvasiveness in highly sensitive immunodeficient mice inoculated intraperitoneally and had greatly reduced neurovirulence in suckling mice inoculated intracerebrally. Compared to the wild-type WN parent, the chimeric virus was highly restricted in replication in both murine and human neuroblastoma cells as well as in brains of suckling mice. The WN/DEN4-delta-30 virus failed to infect geese, indicating that chimerization of WN with DEN4 completely attenuated WN for this avian host. This observation suggests that the WN/DEN4 chimeric viruses would be restricted in their ability to be transmitted from vaccines to domestic or wild birds. In monkeys, the WN/DEN4-delta-30 vaccine candidate was highly immunogenic despite its low level of replication with undetectable viremia. Furthermore, the WN/DEN4-delta-30 vaccine virus was safe and readily induced neutralizing antibodies against WN in monkeys immune to each of the four serotypes of dengue virus. These studies confirm the attenuation of WN/DEN4-delta-30 for non-human primates, including dengue-immune monkeys, and demonstrate both a highly restricted replication (>108-fold decrease) in the brain of mice inoculated IC and an absence of infectivity for birds, findings that indicate this vaccine should be safe for both the recipient and the environment.

Last Modified: 10/25/2014
Footer Content Back to Top of Page